PTC Therapeutics
PTCT
166 hedge funds and large institutions have $1.45B invested in PTC Therapeutics in 2018 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 57 increasing their positions, 42 reducing their positions, and 26 closing their positions.
77% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 26
36% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 42
25% more capital invested
Capital invested by funds: $1.15B → $1.45B (+$292M)
12% more funds holding
Funds holding: 148 → 166 (+18)
4% more call options, than puts
Call options by funds: $24.9M | Put options by funds: $23.9M
9.79% less ownership
Funds ownership: 102.12% → 92.33% (-9.8%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$71.6M |
| 2 |
MWNA
Marshall Wace North America
New York
|
+$32.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$20.8M |
| 4 |
Goldman Sachs
New York
|
+$17.7M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$14.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$113M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$21.8M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$18.2M |
| 4 |
Citigroup
New York
|
-$14.7M |
| 5 |
Two Sigma Investments
New York
|
-$13M |
PTCT Hedge Fund Activity: Q2 2018 in Review
166 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2018, worth a combined $1.45B — up 25% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new PTCT positions and 26 closed out — a net gain of 20 holders — while 57 added to existing stakes and 42 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $71.6M. The largest seller was Scopia Capital Management, cutting an estimated $113M.
- 166 institutional investors held PTC Therapeutics (PTCT) as of Q2 2018, up from 148 in Q1 2018.
- Funds reported $1.45B of PTC Therapeutics stock for Q2 2018, up 25% quarter-over-quarter.
- 46 funds opened new PTC Therapeutics positions in Q2 2018 and 26 closed out, a net change of +20 holders.
- The largest PTC Therapeutics buyer in Q2 2018 was Avoro Capital Advisors, an estimated $71.6M added.
- The largest PTC Therapeutics seller in Q2 2018 was Scopia Capital Management, an estimated $113M sold.
Based on aggregated 13F filings for Q2 2018.